IRCT20211219053452N1
Recruiting
Phase 3
The Effect of Atomoxetine on Cognitive Symptoms in Schizophrenia Patients
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Arak University of Medical Sciences
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Schizophrenia
- •Get a score of 61 or higher on the panss questionnaire
Exclusion Criteria
- •Simultaneous presence of other neurological disorders
- •Any allergy to atomoxetine
- •Patients who have received ECT in the last 6 weeks
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The effect of Atomoxetine on Cognitive Function of Multiple SclerosisMultiple Sclerosis.Demyelinating disease of central nervous system, unspecifiedG37.9IRCT20210715051901N1Ahvaz University of Medical Sciences52
Suspended
Not Applicable
Effects of atomoxetine on cognitive functions in normal subjects using fMRIHealthy adultsJPRN-UMIN000012947ippon Medical School25
Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophreniaIRCT20101130005280N31Mashhad University of Medical Sciences42
Completed
Phase 4
Administration of Paroxetine Attenuates cognitive functon by using fMRI.depressionJPRN-UMIN000002977Tamagawa University30
Not yet recruiting
Phase 3
Atomoxetine for cognitive impairment in Behcet's diseaseIRCT20211206053288N1Tehran University of Medical Sciences40